CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
COMPUGEN LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026
$1.97+0.01 (+0.51%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 5.2
- Dividend yield
- –
Ownership
Who owns Compugen's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 12 sales
Net sold $126.30K
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eran Ophir | President and CEO, Director | 11,375 | 0.01% | Jul 30, 2026 |
| Pierre Ferre | Chief Operating Officer | – | – | Jul 30, 2026 |
| Michelle Mahler | Chief Medical Officer | 36,625 | 0.04% | Jul 30, 2026 |
| Zurit Levine | SVP, Business Development | 47,375 | 0.05% | Jul 30, 2026 |
| David Silberman | Chief Financial Officer | 55,000 | 0.06% | Jul 30, 2026 |
| Russo Sharon Kredo | SVP, Research & Discovery | 37,500 | 0.04% | Jul 30, 2026 |
| Anat Cohen-Dayag | Director | 108,622 | 0.11% | Jul 30, 2026 |
| Eran Perry | Director | 17,500 | 0.02% | Jul 30, 2026 |
| Mathias Hukkelhoven | Director | 17,500 | 0.02% | Jul 30, 2026 |
| Gilead Halevy | Director | 18,907 | 0.02% | Jul 30, 2026 |
| Savitzky Kinneret Livnat | Director | 20,850 | 0.02% | Jul 30, 2026 |
| Sanford S. Zweifach | Director | 20,180 | 0.02% | Jul 30, 2026 |
| Michele Holcomb | Director | 15,000 | 0.02% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Russo Sharon Kredo SVP, Research & Discovery | Jul 29, 2026 | Award | +18,000 | – | – | 37,500 |
| Eran Perry Director | Jul 29, 2026 | Award | +7,500 | – | – | 17,500 |
| David Silberman Chief Financial Officer | Jul 29, 2026 | Award | +19,500 | – | – | 55,000 |
| Mathias Hukkelhoven Director | Jul 29, 2026 | Award | +7,500 | – | – | 17,500 |
| Zurit Levine SVP, Business Development | Jul 29, 2026 | Award | +18,000 | – | – | 47,375 |
| Sanford S. Zweifach Director | Jul 29, 2026 | Award | +7,500 | – | – | 20,180 |
| Michelle Mahler Chief Medical Officer | Jul 29, 2026 | Award | +13,500 | – | – | 36,625 |
| Savitzky Kinneret Livnat Director | Jul 29, 2026 | Award | +7,500 | – | – | 20,850 |
| Gilead Halevy Director | Jul 29, 2026 | Award | +7,500 | – | – | 18,907 |
| Zurit Levine SVP, Business Development | Jul 9, 2026 | Sale(10b5-1 plan) | −1,875 | $2.50 | $4.69K | 29,375 |
| Zurit Levine SVP, Business Development | Jul 9, 2026 | Option exercise | +1,875 | $0.83 | $1.56K | 31,250 |
| Eran Ophir President and CEO, Director | Apr 24, 2026 | Sale(10b5-1 plan) | −5,000 | $3.20 | $16.00K | 11,375 |
| Eran Ophir President and CEO, Director | Apr 24, 2026 | Option exercise | +5,000 | $0.83 | $4.15K | 16,375 |
| Zurit Levine SVP, Business Development | Apr 24, 2026 | Sale(10b5-1 plan) | −2,000 | $3.20 | $6.40K | 29,375 |
| Zurit Levine SVP, Business Development | Apr 24, 2026 | Option exercise | +2,000 | $1.15 | $2.30K | 31,375 |
| Zurit Levine SVP, Business Development | Apr 14, 2026 | Option exercise | +2,000 | $1.15 | $2.30K | 31,375 |
| Zurit Levine SVP, Business Development | Apr 14, 2026 | Sale(10b5-1 plan) | −2,000 | $2.80 | $5.60K | 29,375 |
| Eran Ophir President and CEO, Director | Apr 14, 2026 | Option exercise | +5,000 | $0.83 | $4.15K | 16,375 |
| Eran Ophir President and CEO, Director | Apr 14, 2026 | Sale(10b5-1 plan) | −5,000 | $2.90 | $14.50K | 11,375 |
| Zurit Levine SVP, Business Development | Apr 10, 2026 | Sale(10b5-1 plan) | −3,125 | $2.56 | $8.00K | 29,375 |
| Zurit Levine SVP, Business Development | Apr 10, 2026 | Option exercise | +2,000 | $1.15 | $2.30K | 32,500 |
| Zurit Levine SVP, Business Development | Apr 10, 2026 | Option exercise | +1,125 | $0.83 | $934 | 30,500 |
| Zurit Levine SVP, Business Development | Apr 10, 2026 | Option exercise | +2,000 | $1.15 | $2.30K | 32,500 |
| Zurit Levine SVP, Business Development | Apr 10, 2026 | Option exercise | +1,125 | $0.83 | $934 | 30,500 |
| Zurit Levine SVP, Business Development | Apr 10, 2026 | Sale(10b5-1 plan) | −3,125 | $2.56 | $8.00K | 29,375 |
| Zurit Levine SVP, Business Development | Apr 8, 2026 | Option exercise | +1,000 | $1.15 | $1.15K | 34,750 |
| Zurit Levine SVP, Business Development | Apr 8, 2026 | Option exercise | +4,375 | $0.83 | $3.63K | 33,750 |
| Zurit Levine SVP, Business Development | Apr 8, 2026 | Sale(10b5-1 plan) | −5,375 | $2.42 | $13.01K | 29,375 |
| Zurit Levine SVP, Business Development | Apr 7, 2026 | Sale(10b5-1 plan) | −2,500 | $2.30 | $5.75K | 29,375 |
| Zurit Levine SVP, Business Development | Apr 7, 2026 | Option exercise | +2,500 | $0.83 | $2.08K | 31,875 |
| Zurit Levine SVP, Business Development | Apr 1, 2026 | Option exercise | +1,000 | $1.15 | $1.15K | 32,875 |
| Zurit Levine SVP, Business Development | Apr 1, 2026 | Sale(10b5-1 plan) | −3,500 | $2.20 | $7.70K | 29,375 |
| Zurit Levine SVP, Business Development | Apr 1, 2026 | Option exercise | +2,500 | $0.83 | $2.08K | 31,875 |
| Eran Ophir President and CEO, Director | Apr 1, 2026 | Sale(10b5-1 plan) | −5,625 | $2.21 | $12.43K | 11,375 |
| Eran Ophir President and CEO, Director | Apr 1, 2026 | Option exercise | +5,625 | $0.83 | $4.67K | 17,000 |
| Zurit Levine SVP, Business Development | Mar 26, 2026 | Sale(10b5-1 plan) | −11,875 | $2.04 | $24.23K | 29,375 |
| Zurit Levine SVP, Business Development | Mar 26, 2026 | Option exercise | +11,875 | $0.83 | $9.86K | 41,250 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Eran Ophir Officer | Apr 27, 2026 | 5,000 | $14.60K | Apr 24, 2026 | Employee Stock Option Plan |
| Zurit Levine Officer | Apr 27, 2026 | 4,000 | $11.68K | Apr 24, 2026 | Employee Stock Options plan |
| Zurit Levine Officer | Apr 15, 2026 | 2,000 | $5.52K | Apr 14, 2026 | Employee Stock Options plan |
| Eran Ophir Officer | Apr 15, 2026 | 5,000 | $13.80K | Apr 14, 2026 | Employee Stock Option Plan |
| Zurit Levine Officer | Apr 13, 2026 | 2,000 | $4.96K | Apr 10, 2026 | Employee Stock Options plan |
| Eran Ophir Officer | Apr 2, 2026 | 5,625 | $11.98K | Apr 1, 2026 | Employee Stock Options plan |
| Zurit Levine Officer | Mar 26, 2026 | 24,375 | $50.21K | Mar 26, 2026 | Employee Stock Options plan |